$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Voceryq For Recurrent Respiratory Papillomatosis

Voceryq is the first plasmid DNA immunotherapy the FDA has cleared. In its trial, 27 percent of the hardest-hit patients needed no airway surgery for a year.

TML Health DeskNov 22, 11:43 AM ET · 2 min read
A researcher handles samples in a lab. Voceryq delivers two DNA plasmids that train the immune system on HPV proteins. Image: Pexels, via pexels.com.
Summary

The approval gives adults with recurrent respiratory papillomatosis a treatment aimed at the surgeries themselves, and it rests on 26 patients.

Tap a passage. React to the part that matters.

The FDA approved Voceryq on October 30, the first plasmid DNA immunotherapy cleared for adults with recurrent respiratory papillomatosis.

Recurrent respiratory papillomatosis grows wart-like tumors in the airways, driven by human papillomavirus. The growths return after removal, so standard care is surgery on repeat, sometimes for years. Voceryq's approval covers a narrower promise than a cure. The label says it reduces how often adults need those surgical excisions.

The therapy delivers two plasmids into muscle cells. One carries genetic instructions for specific HPV proteins, and the other carries an immune response enhancer called IL-12. Patients get four doses, one every three weeks, each injected and then driven into cells by Inovio's CELLECTRA 5PSP device, which applies a brief electrical pulse after the injection.

The evidence comes from RRP-001, an open-label single-arm study in 32 adults. Every patient had needed two or more surgeries in the year before treatment. The efficacy population was the 26 patients who had needed three or more, and the trial's full data appeared in Nature Communications and The Laryngoscope.

Seven of those 26 patients, 27 percent, needed no surgery at all in the 12 months after treatment. The FDA's announcement calls that outcome unexpected under the disease's untreated course, since papillomas in this group historically regrow. The confidence interval runs wide, from 12 to 48 percent, and it reflects the small group.

The safety record in the study stayed mild. The common reactions were injection site reactions, headache, fatigue, raised blood pressure, nausea and dizziness, each in more than 5 percent of patients. Most treatment-related reactions graded at level 1 or 2 and passed quickly, and the study recorded no grade 4 or 5 events.

Accelerated approval keeps a condition attached. Inovio must run a confirmatory study that verifies the clinical benefit, and the FDA wants a draft protocol from the company by the end of 2026. The two sides aim to settle the final protocol by mid-2027, and the approval can be revisited if the benefit doesn't confirm.

Voceryq is the second immunotherapy to reach this disease in just over a year. The FDA cleared Papzimeos, an adenoviral vector therapy, for the same patients in 2025. Inovio expects Voceryq to be available to order in about 60 days, with the full commercial launch in the first quarter of 2027.

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.